glp-1 heart muscle Mechanisms of Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit GLP-1 Receptor Agonists in Heart

Visual loss is observed in greater than 90% of those with IIH 18 with up to 25% suffering marked visual impairment

A comprehensive analysis of 43,365 individuals from two US healthcare databases indicated that GLP-1 RAs do not elevate the risk of pulmonary aspiration during upper gastrointestinal endoscopy in patients with T2DM when compared to SGLT-2 inhibitors, yielding a pooled risk ratio of 0.98 (95% CI, 0.73 to 1.31) among GLP-1 RA users

Recently, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gradually become a first-line treatment for type 2 diabetes [7]

But we do not confuse a medication with a prevention strategy